Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Jun 5;18(1):41.
doi: 10.1186/s40360-017-0148-3.

Tardive akathisia related to the anti-hypertensive agent Sevikar-a case report

Men-Ting Hsieh  1 , Pao-Yen Lin  1 , Chia-Jen Tsai  2 , Chiung-Chih Chang  3 , Yu Lee  4
Affiliations
Case Reports

Tardive akathisia related to the anti-hypertensive agent Sevikar-a case report

Men-Ting Hsieh et al. BMC Pharmacol Toxicol. .

Abstract

Background: Tardive akathisia (TA) is a subtype of tardive syndrome, and its etiology is still uncertain. Sevikar is an anti-hypertensive agent containing both amlodipine and olmesartan, and has never been reported to have an adverse reaction in patients with tardive syndrome.

Case presentation: A 57-year-old woman who took Sevikar for hypertension for 10 years developed TA one and a half years before receiving any psychiatric treatment. After switching from Sevikar to bisoprolol, she reported obvious improvement in her akathisia.

Conclusions: It is noteworthy that her TA developed before receiving any antidepressant medication, and that her TA improved after discontinuation of Sevikar. In light of these pharmacodynamic properties, it is therefore concluded that use of amlodipine and olmesartan might have caused TA in this patient. We reported this rare case to remind clinicians to be aware of possible akathisia when using amlodipine and olmesartan in combination as anti-hypertensive agents.

Keywords: Amlodipine; Angiotensin II receptor blocker; Anti-hypertensive agent; Calcium-channel blocker; Olmesartan; Sevikar; Tardive akathisia.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Tarsy D, Baldessarini RJ. Tardive dyskinesia. Annu Rev Med. 1984;35:605–23. doi: 10.1146/annurev.me.35.020184.003133. - DOI - PubMed
    1. Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol. 1995;18:197–214. doi: 10.1097/00002826-199506000-00001. - DOI - PubMed
    1. Kohlhardt M, Fleckenstein A. Inhibition of the slow inward current by nifedipine in mammalian ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol. 1977;298:267–72. doi: 10.1007/BF00500899. - DOI - PubMed
    1. Burnier M, Brunner H. Angiotensin II receptor antagonists. Lancet. 2000;355:637–45. doi: 10.1016/S0140-6736(99)10365-9. - DOI - PubMed
    1. Chouinard G, Margolese HC. Manual for the extrapyramidal symptom rating scale (ESRS) Schizophr Res. 2005;76:247–65. doi: 10.1016/j.schres.2005.02.013. - DOI - PubMed

Publication types

MeSH terms

Substances